• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hematology/Oncology Clinics of North America >Cytotoxic Chemotherapy in Advanced Pancreatic Cancer
【24h】

Cytotoxic Chemotherapy in Advanced Pancreatic Cancer

机译：Cytotoxic Chemotherapy in Advanced Pancreatic Cancer

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Despite the progress in our understanding of the molecular tumor biology in PDAC, we have not yet translated these insights into improved treatment options for metastatic pancreatic cancer. Our options are limited to a few key cytotoxic therapies including FOLFIRINOX, gemcitabine-nab-paclitaxel, nanoliposomal irinotecan, and 5-FU, and thus there is still a lot of work to be done in this condition. Better systemic treatment of pancreatic cancer beyond conventional chemotherapy is expected in the near future, thanks to a better understanding of pancreatic cancer tumor biology, the growing availability of noncytotoxic agents, and interest from academia and pharma-ceutical companies to meet the challenge. It is unclear whether trials like NCI-MATCH (National Malignancy Institute Molecular Analysis for Therapy Choice) and others that assign drugs based on genetic abnormalities (actionable mutations) would be suc-cessful in this cancer because there are not many "hits. " However, it is obvious that we can only push the therapeutic envelope in this condition with profound science that includes robust translational applications and vigorous recruitment efforts to research studies. The progress in PDAC has been slow but meaningful.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号